Dapagliflozin aids glycemic control in type 2 diabetes

March 20, 2012
Dapagliflozin aids glycemic control in type 2 diabetes

(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research published in the March 20 issue of the Annals of Internal Medicine.

To evaluate the efficacy and safety of dapagliflozin, John P.H. Wilding, D.M., of University Hospital Aintree in Liverpool, U.K., and associates randomly assigned 800 patients with inadequately controlled , receiving at least 30 units of insulin daily, with or without up to two oral antidiabetic drugs, to receive a daily dose of dapagliflozin (2.5, 5, or 10 mg) or placebo for 48 weeks.

After 24 weeks, the researchers found that patients taking dapagliflozin had a 0.79 to 0.96 percent decrease in mean hemoglobin A1c, compared with a 0.39 percent decrease with placebo. The daily insulin dose decreased by 0.63 units with dapagliflozin compared with an increase of 5.65 units in the . Dapagliflozin was associated with a decrease of 0.92 to 1.61 kg in body weight, compared with an increase of 0.43 kg in the placebo group. At 48 weeks, these effects were maintained. Patients in the pooled dapagliflozin groups had a higher rate of hypoglycemic episodes compared with the placebo group (56.6 versus 51.8 percent).

"Dapagliflozin improves glycemic control, stabilizes insulin dosing, and reduces weight without increasing major in patients with inadequately controlled ," the authors write.

The study was funded by AstraZeneca and Bristol-Myers Squibb, co-developers of dapagliflozin. Several of the authors are employees of AstraZeneca.

Explore further: New type 2 diabetes drug helps lower blood sugar: study

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

New type 2 diabetes drug helps lower blood sugar: study

March 20, 2012
(HealthDay) -- A new type of medication for type 2 diabetes helps to lower blood sugar levels when used in concert with insulin and other diabetes drugs, new research suggests.

FDA questions safety of experimental diabetes drug

July 15, 2011
(AP) -- Federal health regulators have concerns about bladder and breast cancer seen in patients taking an experimental diabetes pill from Bristol-Myers Squibb and AstraZeneca.

New drug improves glucose control without increasing risk of hypoglycemia in type 2 diabetes patients

February 26, 2012
TAK-875, a new treatment for type 2 diabetes, improves glycaemic (blood sugar) control and is equally as effective as the sulphonylurea glimepiride (a common drug treatment) but has a significantly lower risk of hypoglycaemia ...

Study suggests drug significantly improves glycemic control in type one diabetics on insulin

June 15, 2011
Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide, an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control ...

Recommended for you

Insulin pill may delay type 1 diabetes in some

November 21, 2017
(HealthDay)—It's often said that timing is everything. New research suggests this may be true when giving an insulin pill to try to prevent or delay type 1 diabetes.

Controlling diabetes with your phone might be possible someday

November 21, 2017
Think about this. You have diabetes, are trying to control your insulin levels and instead of taking a pill or giving yourself an injection, you click an app on your phone that tells your pancreas to bring blood sugar levels ...

Simple test predicts diabetes remission following weight loss surgery

November 21, 2017
A new simple test that helps predicts which people with type 2 diabetes will benefit most from weight loss surgery has been developed by a UCL-led team.

Pre-diabetes discovery marks step towards precision medicine

November 20, 2017
Researchers from the University of Sydney's Charles Perkins Centre have identified three specific molecules that accurately indicate insulin resistance, or pre-diabetes - a major predictor of metabolic syndrome, the collection ...

Scientists reverse diabetes in a mouse model using modified blood stem cells

November 15, 2017
Researchers at Boston Children's Hospital have successfully reversed type 1 diabetes in a mouse model by infusing blood stem cells pre-treated to produce more of a protein called PD-L1, which is deficient in mice (and people) ...

Pregnancy-related conditions taken together leave moms—and dads—at risk

November 14, 2017
Research has already shown that women who develop either diabetes or high blood pressure during pregnancy are at risk of getting type 2 diabetes, high blood pressure or heart disease years later. Now, a new study from a team ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.